2. The question arises whether apart from the codon 129, any other factors might modify the phenotype associated with V180I. Authors do mention the role of different PrPsc glycotypes. It would be helpful to know whether in this cohort they have data on the variability of the immunoblotting pattern in at least some of the V180I cases examined.
3. The patients with V180I are elder than the sporadic CJD group. Do the authors have data at least in some of the cases examined, whether there are additional neuropathological alterations in these patients (like Alzheimer`s disease-related etc).
4. It would be interesting to compare the laboratory findings in a group of V180I and sporadic CJD patients who are elderly (e.g. above 75 years). This is to exclude whether some of the variables are age-dependent. Alternatively, here authors could consider to perform further statistical analysis (multivariate) to evaluate the combined effect of age, codon 129, and the PRNP mutation (or its lack) on the laboratory findings (e.g. amount of tau, positive rate of PrPSc, PSWC). Table 1 , the total number of gCJDV180I is 44 while in Table 2 , the combination of gCJDV180I-129MM (n=36) and gCJD-129MV (n=7) is 43. The authors should resolve this discrepancy.
VERSION 1 -AUTHOR RESPONSE
Reviewer Gabor G. Kovacs: 1) To compare the clinical spectrum with MM type 2 sporadic CJD (even if only literature data in the Discussion).
According to both the reviewers' suggestions, we have changed our Table 1 to Tables 2 and 3 , and compared among V180I-MM/sCJDMM1/sCJDMM2, or between V180I-MV/sCJD-MV.
2) The question arises whether apart from the codon 129, any other factors might modify the phenotype associated with V180I. Authors do mention the role of different PrPsc glycotypes. It would be helpful to know whether in this cohort they have data on the variability of the immunoblotting pattern in at least some of the V180I cases examined.
We have revised the manuscript accordingly.
3) The patients with V180I are elder than the sporadic CJD group. Do the authors have data at least in some of the cases examined, whether there are additional neuropathological alterations in these patients (like Alzheimer`s disease-related etc).
We have made another table (Table 5 ) to compare patients with V180I to patients with sCJD older than 75 years and found there was no significant difference.
4) It would be interesting to compare the laboratory findings in a group of V180I and sporadic CJD patients who are elderly (e.g. above 75 years). This is to exclude whether some of the variables are age-dependent. Alternatively, here authors could consider to perform further statistical analysis (multivariate) to evaluate the combined effect of age, codon 129, and the PRNP mutation (or its lack) on the laboratory findings (e.g. amount of tau, positive rate of PrPSc, PSWC).
We have made another table (Table 5 ) to compare patients with V180I to patients with sCJD older than 75 years, and found there was no significant difference. As to multivariate analysis of the amount of tau, the distribution of tau values did not follow normal probability distribution, and that could not be corrected. Positive rates of PrPSc, and PSWC and tau were analyzed by logistic regression analysis, and there was no significant factor.
5) The last sentence in the Abstract/Results is difficult to understand, please write it more clearly.
6) How many V180I cases were definite and neuropathologically evaluated? Are the definite and probable V180I cases different in any variables?
We have revised the manuscript accordingly. Briefly, there were 16 defined patients so far, and there was no difference between probable and definite cases.
Reviewer Wenquan Zou: 1) Since the patients with gCJDV180I often are misdiagnosed as Alzheimer's and other dementia diseases, it will be very helpful to the clinicians if the authors include a new table to differentiate the clinical features of gCJDV180I from Alzheimer's disease.
We have made another table accordingly.
2) It is very interesting that while no significant differences in clinical features, EEG and MRI are observed between 129MM and 129MV of gCJDV180I, CSF biomarkers including 14-3-3 protein, tau protein and PrPSc are significant higher in 129MM than in 129MV. The authors may want to discuss the potential molecular mechanisms.
We have revised the Discussion accordingly.
3) The authors do not provide more info about the protocol for RT-QuIC. For instance, does the recombinant human PrP used include 129M or 129V? Could the difference in the polymorphism at residue 129 between the substrate and the seed affect the positive result of CSF PrPSc test? How
